Published in J Clin Oncol on February 01, 1997
Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 3.45
Principles of adoptive T cell cancer therapy. J Clin Invest (2007) 2.65
Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol (2010) 1.40
Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res (2008) 1.38
Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother (2008) 1.04
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun (2006) 1.04
Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J Immunother (2009) 0.97
Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses. Cancer Res (2008) 0.94
Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J Immunol (2009) 0.89
Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis. Rheumatol Int (2008) 0.89
Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol (2002) 0.85
Post-transplant adoptive T-cell immunotherapy. Best Pract Res Clin Haematol (2008) 0.81
Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells. Int J Biol Sci (2009) 0.80
Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice. J Immunother (2013) 0.80
Expansion of melanoma-specific T cells from lymph nodes of patients in stage III: implications for adoptive immunotherapy in treating cancer. Surgery (2012) 0.79
Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer. Cancer Immunol Immunother (2015) 0.79
Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Hum Vaccin Immunother (2014) 0.77
Cloning, purification and bioactivity assay of human CD28 single-chain antibody in Escherichia coli. Cytotechnology (2009) 0.76
Assessment of the number of local cytotoxic T lymphocytes required for degradation of micrometer-size tumor spheroids. Cytotechnology (2001) 0.75
Technical Considerations for the Generation of Adoptively Transferred T Cells in Cancer Immunotherapy. Cancers (Basel) (2016) 0.75
Clinical course and immune response of a renal cell carcinoma patient to adoptive transfer of autologous cytotoxic T lymphocytes. Clin Exp Immunol (2003) 0.75
Crystal structure of rhodopsin: A G protein-coupled receptor. Science (2000) 28.60
An integrated computational pipeline and database to support whole-genome sequence annotation. Genome Biol (2002) 5.24
Improved recognition of native-like protein structures using a combination of sequence-dependent and sequence-independent features of proteins. Proteins (1999) 4.86
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Two-year incidence, remission, and change patterns of urinary incontinence in noninstitutionalized older adults. J Gerontol (1990) 4.24
Nucleotide sequence specifying the glycoprotein gene, gB, of herpes simplex virus type 1. Virology (1984) 3.34
BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene (2007) 3.19
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 3.08
Nucleotide sequence of a region of the herpes simplex virus type 1 gB glycoprotein gene: mutations affecting rate of virus entry and cell fusion. Virology (1984) 2.95
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer (2010) 2.83
A centimeter here, a centimeter there: does it matter? J Am Acad Dermatol (1995) 2.67
Proposal of the genera Anaerococcus gen. nov., Peptoniphilus gen. nov. and Gallicola gen. nov. for members of the genus Peptostreptococcus. Int J Syst Evol Microbiol (2001) 2.59
The Neurospora clock gene frequency shares a sequence element with the Drosophila clock gene period. Nature (1989) 2.44
Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A (1993) 2.35
X-Ray diffraction analysis of three-dimensional crystals of bovine rhodopsin obtained from mixed micelles. J Struct Biol (2000) 1.88
Liposarcoma of the spermatic cord: report of 6 cases and review of the literature. J Urol (1995) 1.76
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res (2000) 1.74
The nucleotide sequence of the gB glycoprotein gene of HSV-2 and comparison with the corresponding gene of HSV-1. Virology (1986) 1.71
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst (1995) 1.67
A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation. Hepatology (1995) 1.56
Transport of C4-dicarboxylic acids in salmonella typhimurium. Arch Biochem Biophys (1978) 1.49
Clinical and cystometric characteristics of continent and incontinent noninstitutionalized elderly. J Urol (1988) 1.49
Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res (2000) 1.46
Measurement by radioimmunoassay of prostaglandins as their methyl oximes. Prostaglandins Leukot Med (1986) 1.43
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol (1985) 1.40
Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol (2001) 1.37
Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol (1997) 1.36
Small-area variation in hospital discharge rates. Do socioeconomic variables matter? Med Care (1989) 1.33
CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol (2000) 1.29
An enlarged largest subunit of Plasmodium falciparum RNA polymerase II defines conserved and variable RNA polymerase domains. Nucleic Acids Res (1989) 1.27
Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol (1991) 1.27
Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res (1999) 1.26
p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation in primary murine T cells. J Immunol (1999) 1.25
Definition of the supraclavicular and infraclavicular nodes: implications for three-dimensional CT-based conformal radiation therapy. Radiology (2001) 1.23
Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol (1992) 1.22
Pemphigus antibody action on skin explants: kinetics of acantholytic changes and stability of antigens in tissue cultures of normal monkey skin explants. Arch Dermatol (1977) 1.21
Prophylactic 5-Fr pancreatic duct stents are superior to 3-Fr stents: a randomized controlled trial. Endoscopy (2011) 1.20
Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol (2001) 1.19
Age-related differences in breast cancer treatment. Ann Surg Oncol (1994) 1.18
Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol (2000) 1.17
Studies on defined immunofluorescence in clinical immunopathology. II. Relationship of F/P ratios pf conjugates and staining properties in indirect immunofluorescence. Ann N Y Acad Sci (1975) 1.14
Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of resistance and cytotoxicity. Proc Natl Acad Sci U S A (1992) 1.12
Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res (2001) 1.09
Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res (1984) 1.09
Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther (1996) 1.08
T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res (2000) 1.08
The multidisciplinary melanoma clinic: a cost outcomes analysis of specialty care. J Am Acad Dermatol (1998) 1.08
Methods used to manage urinary incontinence by older adults in the community. J Am Geriatr Soc (1989) 1.07
Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. J Leukoc Biol (1997) 1.07
Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol (2010) 1.07
Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer (1984) 1.04
Incidence and titers of antinuclear, antismooth muscle, and other autoantibodies in blood donors. J Lab Clin Med (1975) 1.03
Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-κB: implication in breast cancer metastasis. Oncogene (2011) 1.03
A molecular genetic intervention for AIDS--effects of a transdominant negative form of Rev. Hum Gene Ther (1994) 1.03
Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res (1993) 1.02
Current status of adoptive immunotherapy of cancer. Crit Rev Oncol Hematol (1996) 1.02
Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol (1997) 1.01
CT of recurrent retroperitoneal sarcomas. AJR Am J Roentgenol (2000) 1.01
Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res (1996) 1.01
Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res (1992) 1.00
Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol (1998) 1.00
Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A (1996) 0.99
Complete spontaneous regression of pulmonary metastatic melanoma. Dermatol Surg (1998) 0.99
Correlation of the local and systemic cytokine response with clinical outcome following thermal injury. J Trauma (1993) 0.98
Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg (1998) 0.98
Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s). Cancer Res (1985) 0.98
Lipophorin of female Blattella germanica (L.): characterization and relation to hemolymph titers of juvenile hormone and hydrocarbons. J Insect Physiol (1999) 0.98
Malignant melanoma of the foot and ankle. J Bone Joint Surg Am (1995) 0.97
Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res (1992) 0.97
Characterization of the gene encoding the largest subunit of Plasmodium falciparum RNA polymerase III. Mol Biochem Parasitol (1991) 0.97
Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy. J Immunol (2001) 0.97
Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells. Cancer Immunol Immunother (1995) 0.97
Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer (2001) 0.97
T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics. J Immunol (2000) 0.96
Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res (1985) 0.96
Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother (1996) 0.96
Nuclear deposits of immunoglobulins in skin of patients with systemic lupus erythematosus. Clin Exp Immunol (1977) 0.95
Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol (1999) 0.94
Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol (1998) 0.94
Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res (1986) 0.94
Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J Immunol (1988) 0.94
Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy. Arch Surg (1991) 0.93
Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol (1994) 0.93
Hemolymph juvenile hormone titers in pupal and adult stages of southwestern corn borer [Diatraea grandiosella (pyralidae)] and relationship with egg development. J Insect Physiol (1997) 0.92
Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther (2012) 0.92
Description of Arthrobacter creatinolyticus sp. nov., isolated from human urine. Int J Syst Bacteriol (1998) 0.92
Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study. Am J Transplant (2008) 0.92
Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism. J Clin Invest (1997) 0.91
Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum Gene Ther (2000) 0.91
Proton MR spectroscopy after acute central nervous system injury: outcome prediction in neonates, infants, and children. Radiology (1997) 0.91
Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol (2010) 0.91
The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis. Clin Exp Immunol (2011) 0.91